Summary & Overview
HCPCS G9895: Documentation of Omission of Androgen Deprivation with Prostate Radiotherapy
HCPCS Level II code G9895 documents the clinical rationale for not prescribing or administering androgen deprivation therapy (ADT) in conjunction with external beam radiotherapy to the prostate, such as when ADT is intentionally omitted during salvage therapy. Nationally, clear documentation of treatment decisions affects coverage determinations, quality reporting, and care coordination in prostate cancer radiation management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication explains how payers treat documentation of ADT omission, the contexts in which G9895 is used, and implications for billing, prior authorization, and clinical records.
Readers will learn the clinical context for using G9895, the typical service setting (radiation oncology clinics and hospital outpatient radiation therapy), and common administrative considerations tied to this documentation code. The report summarizes benchmark practices, highlights relevant policy and coverage considerations, and outlines how accurate documentation using G9895 supports claims processing and payer review. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G9895 documents the medical reason(s) for not prescribing or administering androgen deprivation therapy (ADT) in combination with external beam radiotherapy to the prostate (for example, when ADT is omitted during salvage therapy). This code captures clinical rationale when ADT is intentionally not used alongside prostate external beam radiotherapy.
-
Service type: Clinical documentation of treatment decision-making related to systemic therapy omission in radiation oncology
-
Typical site of service: Radiation oncology clinic or hospital outpatient radiation therapy setting
Clinical & Coding Specifications
Clinical Context
A typical patient is a man with a history of localized prostate cancer treated previously with radical prostatectomy or primary radiotherapy who presents for evaluation of biochemical recurrence or for planning of salvage external beam radiotherapy to the prostate or prostate bed. In the radiation oncology clinic the radiation oncologist documents the decision-making process and clinical rationale for not prescribing or administering concurrent androgen deprivation therapy (ADT) with external beam radiotherapy. Common reasons documented include prior adverse effects or intolerance to ADT (e.g., severe hot flashes, thromboembolic events, uncontrolled diabetes or metabolic complications), patient refusal after informed discussion of risks and benefits, significant comorbidities that increase risk of ADT (e.g., recent myocardial infarction, uncontrolled heart failure), limited life expectancy where ADT risks outweigh potential benefit, or prior long-term ADT exposure making additional ADT inappropriate. The workflow includes review of prior oncologic treatments and comorbidities, discussion with the patient and family, shared decision-making documentation, and placement of the appropriate billing entry G9895 to reflect that a medical reason(s) for omission of ADT was documented in the medical record. Typical sites of service are outpatient radiation oncology clinics, hospital-based radiation oncology departments, or ambulatory surgical centers providing EBRT planning and delivery.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |